Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26623
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchlapbach, Luregn J-
dc.contributor.authorGibbons, Kristen-
dc.contributor.authorRidolfi, Roberta-
dc.contributor.authorHarley, Amanda-
dc.contributor.authorCree, Michele-
dc.contributor.authorLong, Debbie-
dc.contributor.authorBuckley, David-
dc.contributor.authorErickson, Simon-
dc.contributor.authorFesta, Marino-
dc.contributor.authorGeorge, Shane-
dc.contributor.authorKing, Megan-
dc.contributor.authorSingh, Puneet-
dc.contributor.authorRaman, Sainath-
dc.contributor.authorBellomo, Rinaldo-
dc.date2021-04-30-
dc.date.accessioned2021-05-31T22:59:08Z-
dc.date.available2021-05-31T22:59:08Z-
dc.date.issued2021-04-30-
dc.identifier.citationFrontiers in Pediatrics 2021; 9: 663435en
dc.identifier.issn2296-2360
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26623-
dc.description.abstractIntroduction: Septic shock remains amongst the leading causes of childhood mortality. Therapeutic options to support children with septic shock refractory to initial resuscitation with fluids and inotropes are limited. Recently, the combination of intravenous hydrocortisone with high dose ascorbic acid and thiamine (HAT therapy), postulated to reduce sepsis-related organ dysfunction, has been proposed as a safe approach with potential for mortality benefit, but randomized trials in paediatric patients are lacking. We hypothesize that protocolised early use of HAT therapy ("metabolic resuscitation") in children with septic shock is feasible and will lead to earlier resolution of organ dysfunction. Here, we describe the protocol of the Resuscitation in Paediatric Sepsis Using Metabolic Resuscitation-A Randomized Controlled Pilot Study in the Paediatric Intensive Care Unit (RESPOND PICU). Methods and Analysis: The RESPOND PICU study is an open label randomized-controlled, two-sided multicentre pilot study conducted in paediatric intensive care units (PICUs) in Australia and New Zealand. Sixty children aged between 28 days and 18 years treated with inotropes for presumed septic shock will be randomized in a 1:1 ratio to either metabolic resuscitation (1 mg/kg hydrocortisone q6h, 30 mg/kg ascorbic acid q6h, 4 mg/kg thiamine q12h) or standard septic shock management. Main outcomes include feasibility of the study protocol and survival free of organ dysfunction censored at 28 days. The study cohort will be followed up at 28-days and 6-months post enrolment to assess neurodevelopment, quality of life and functional status. Biobanking will allow ancillary studies on sepsis biomarkers. Ethics and Dissemination: The study received ethical clearance from Children's Health Queensland Human Research Ethics Committee (HREC/18/QCHQ/49168) and commenced enrolment on June 12th, 2019. The primary study findings will be submitted for publication in a peer-reviewed journal. Trial Registration: Australian and New Zealand Clinical Trials Registry (ACTRN12619000829112). Protocol Version: V1.8 22/7/20.en
dc.language.isoeng
dc.subjectascorbic aciden
dc.subjectchilden
dc.subjecthydrocortisoneen
dc.subjectintensive careen
dc.subjectsepsisen
dc.subjectseptic shocken
dc.subjectthiamineen
dc.subjectvitamin Cen
dc.titleResuscitation in Paediatric Sepsis Using Metabolic Resuscitation-A Randomized Controlled Pilot Study in the Paediatric Intensive Care Unit (RESPOND PICU): Study Protocol and Analysis Plan.en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in Pediatricsen
dc.identifier.affiliationPediatric and Neonatal Intensive Care Unit, and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerlanden
dc.identifier.affiliationPaediatric Intensive Care Unit, Starship Children's Hospital, Auckland, New Zealanden
dc.identifier.affiliationIntensive Careen
dc.identifier.affiliationChild Health Research Centre, The University of Queensland, and Paediatric Intensive Care Unit, Queensland Children's Hospital, Brisbane, QLD, Australiaen
dc.identifier.affiliationPharmacy Department, Queensland Children's Hospital, Brisbane, QLD, Australiaen
dc.identifier.affiliationSchool of Nursing, Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, QLD, Australiaen
dc.identifier.affiliationPaediatric Critical Care Unit, Perth Children's Hospital, Perth, WA, Australiaen
dc.identifier.affiliationDepartments of Emergency Medicine and Children's Critical Care, Gold Coast University Hospital, Southport, QLD, Australiaen
dc.identifier.affiliationSchool of Medicine and Menzies Health Institute Queensland, Griffith University, Southport, QLD, Australiaen
dc.identifier.affiliationSchool of Nursing, Midwifery and Social Work, University of Queensland, Brisbane, QLD, Australiaen
dc.identifier.affiliationPaediatric Intensive Care Unit, Children's Hospital Westmead, Sydney, NSW, Australiaen
dc.identifier.affiliationKids Critical Care Research Group, Kids Research, Sydney Children's Hospitals Network, Sydney, NSW, Australiaen
dc.identifier.affiliationPaediatric Intensive Care Unit, Sydney Children's Hospital, Sydney, NSW, Australiaen
dc.identifier.affiliationMonash University, Melbourne, VIC, Australiaen
dc.identifier.doi10.3389/fped.2021.663435en
dc.type.contentTexten
dc.identifier.pubmedid34041208
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.